98 related articles for article (PubMed ID: 9328216)
21. Pharmacokinetics and safety of a fully human hepatocyte growth factor antibody, AMG 102, in cynomolgus monkeys.
Kakkar T; Ma M; Zhuang Y; Patton A; Hu Z; Mounho B
Pharm Res; 2007 Oct; 24(10):1910-8. PubMed ID: 17520181
[TBL] [Abstract][Full Text] [Related]
22. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration.
Mordenti J; Cuthbertson RA; Ferrara N; Thomsen K; Berleau L; Licko V; Allen PC; Valverde CR; Meng YG; Fei DT; Fourre KM; Ryan AM
Toxicol Pathol; 1999; 27(5):536-44. PubMed ID: 10528633
[TBL] [Abstract][Full Text] [Related]
23. [Effect of humanized anti-interleukin-6 receptor antibody on new xenograft model of multiple myeloma].
Shimazaki C; Goto H
Rinsho Ketsueki; 1997 Apr; 38(4):281-4. PubMed ID: 9146051
[No Abstract] [Full Text] [Related]
24. Whole-molecule antibody engineering: generation of a high-affinity anti-IL-6 antibody with extended pharmacokinetics.
Finch DK; Sleeman MA; Moisan J; Ferraro F; Botterell S; Campbell J; Cochrane D; Cruwys S; England E; Lane S; Rendall E; Sinha M; Walker C; Rees G; Bowen MA; Schneider A; Liang M; Faggioni R; Fung M; Mallinder PR; Wilkinson T; Kolbeck R; Vaughan T; Lowe DC
J Mol Biol; 2011 Aug; 411(4):791-807. PubMed ID: 21723291
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics and safety of bevacizumab administered in combination with cisplatin and paclitaxel in cynomolgus monkeys.
Xu L; Zuch CL; Lin YS; Modi NB; Lum BL
Cancer Chemother Pharmacol; 2008 Apr; 61(4):607-14. PubMed ID: 17549476
[TBL] [Abstract][Full Text] [Related]
26. Cynomolgus monkey model of interleukin-31-induced scratching depicts blockade of human interleukin-31 receptor A by a humanized monoclonal antibody.
Oyama S; Kitamura H; Kuramochi T; Higuchi Y; Matsushita H; Suzuki T; Goto M; Adachi H; Kasutani K; Sakamoto A; Iwayanagi Y; Kaneko A; Nanami M; Fujii E; Esaki K; Takashima Y; Shimaoka S; Hattori K; Kawabe Y
Exp Dermatol; 2018 Jan; 27(1):14-21. PubMed ID: 27714851
[TBL] [Abstract][Full Text] [Related]
27. Immunization against an IL-6 peptide induces anti-IL-6 antibodies and modulates the Delayed-Type Hypersensitivity reaction in cynomolgus monkeys.
Desallais L; Bouchez C; Mouhsine H; Moreau G; Ratsimandresy R; Montes M; Do H; Quintin-Colonna F; Zagury JF
Sci Rep; 2016 Jan; 6():19549. PubMed ID: 26782790
[TBL] [Abstract][Full Text] [Related]
28. The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis.
Van Roy M; Ververken C; Beirnaert E; Hoefman S; Kolkman J; Vierboom M; Breedveld E; 't Hart B; Poelmans S; Bontinck L; Hemeryck A; Jacobs S; Baumeister J; Ulrichts H
Arthritis Res Ther; 2015 May; 17(1):135. PubMed ID: 25994180
[TBL] [Abstract][Full Text] [Related]
29. Generation and characterization of a potent fully human monoclonal antibody against the interleukin-23 receptor.
Sasaki-Iwaoka H; Ohori M; Imasato A; Taguchi K; Minoura K; Saito T; Kushima K; Imamura E; Kubo S; Furukawa S; Morokata T
Eur J Pharmacol; 2018 Jun; 828():89-96. PubMed ID: 29588152
[TBL] [Abstract][Full Text] [Related]
30. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia.
Klein B; Wijdenes J; Zhang XG; Jourdan M; Boiron JM; Brochier J; Liautard J; Merlin M; Clement C; Morel-Fournier B
Blood; 1991 Sep; 78(5):1198-204. PubMed ID: 1715218
[TBL] [Abstract][Full Text] [Related]
31. Preclinical safety and pharmacology of an anti-human interleukin-13 monoclonal antibody in normal macaques and in macaques with allergic asthma.
Martin PL; Fisher D; Glass W; O'Neil K; Das A; Martin EC; Li L
Int J Toxicol; 2008; 27(5):351-8. PubMed ID: 19037805
[TBL] [Abstract][Full Text] [Related]
32. Establishment of a new interleukin-6 (IL-6) receptor inhibitor applicable to the gene therapy for IL-6-dependent tumor.
Yoshio-Hoshino N; Adachi Y; Aoki C; Pereboev A; Curiel DT; Nishimoto N
Cancer Res; 2007 Feb; 67(3):871-5. PubMed ID: 17283116
[TBL] [Abstract][Full Text] [Related]
33. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
[TBL] [Abstract][Full Text] [Related]
34. Preclinical pharmacokinetics and safety of Sym004: a synergistic antibody mixture directed against epidermal growth factor receptor.
Skartved NJ; Jacobsen HJ; Pedersen MW; Jensen PF; Sen JW; Jørgensen TK; Hey A; Kragh M
Clin Cancer Res; 2011 Sep; 17(18):5962-72. PubMed ID: 21825041
[TBL] [Abstract][Full Text] [Related]
35. Epitope peptides from interleukin-6 receptor which inhibit the growth of human myeloma cells.
Halimi H; Eisenstein M; Oh JW; Revel M; Chebath J
Eur Cytokine Netw; 1995; 6(3):135-43. PubMed ID: 8589270
[TBL] [Abstract][Full Text] [Related]
36. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of a surrogate antibody for preclinical safety testing of an anti-CD11a monoclonal antibody.
Clarke J; Leach W; Pippig S; Joshi A; Wu B; House R; Beyer J
Regul Toxicol Pharmacol; 2004 Dec; 40(3):219-26. PubMed ID: 15546677
[TBL] [Abstract][Full Text] [Related]
38. Quantitative determination of humanized monoclonal antibody rhuMAb2H7 in cynomolgus monkey serum using a Generic Immunoglobulin Pharmacokinetic (GRIP) assay.
Yang J; Ng C; Lowman H; Chestnut R; Schofield C; Sandlund B; Ernst J; Bennett G; Quarmby V
J Immunol Methods; 2008 Jun; 335(1-2):8-20. PubMed ID: 18402977
[TBL] [Abstract][Full Text] [Related]
39. Designer cytokines: targeting actions to cells of choice.
Economides AN; Ravetch JV; Yancopoulos GD; Stahl N
Science; 1995 Nov; 270(5240):1351-3. PubMed ID: 7481821
[TBL] [Abstract][Full Text] [Related]
40. Nonclinical safety of mavrilimumab, an anti-GMCSF receptor alpha monoclonal antibody, in cynomolgus monkeys: relevance for human safety.
Ryan PC; Sleeman MA; Rebelatto M; Wang B; Lu H; Chen X; Wu CY; Hinrichs MJ; Roskos L; Towers H; McKeever K; Dixit R
Toxicol Appl Pharmacol; 2014 Sep; 279(2):230-9. PubMed ID: 24937321
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
